| P50 | author | Wilbert S Aronow | Q67208280 |
| P2093 | author name string | Kirk Sperber | |
| | Julia Y Ash | |
| | Deborah L Shapiro | |
| | Chun Peng Chao | |
| | Crispin Abarientos | |
| P2860 | cites work | Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo | Q27485211 |
| | Toll-like receptors | Q27860671 |
| | Anti-inflammatory and immunosuppressive drugs and reproduction | Q28218219 |
| | Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) | Q31107094 |
| | Hydroxychloroquine in lupus pregnancy | Q33373145 |
| | Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases | Q33445361 |
| | Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort | Q33455990 |
| | Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy | Q33478819 |
| | Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases | Q33579097 |
| | Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. | Q33731760 |
| | Effects of weakly basic amines on proteolytic processing and terminal glycosylation of secretory proteins in cultured rat hepatocytes | Q34180904 |
| | Antimalarial drugs in systemic lupus erythematosus: use in pregnancy | Q34458596 |
| | Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents | Q34556950 |
| | Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications | Q34583259 |
| | Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity | Q34626216 |
| | IL-17 and the Th17 lineage in systemic lupus erythematosus | Q34807773 |
| | Pharmacogenetics of disease-modifying anti-rheumatic drugs | Q35761889 |
| | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature | Q36049718 |
| | Influence of hydroxychloroquine on the bioavailability of oral metoprolol | Q36055442 |
| | Antirheumatic drugs in pregnancy and lactation | Q36272347 |
| | Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells | Q36275163 |
| | Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells | Q36350981 |
| | RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. | Q36403678 |
| | Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future | Q36592626 |
| | The dominant self and the cryptic self: shaping the autoreactive T-cell repertoire | Q36676063 |
| | Ocular adverse effects associated with systemic medications : recognition and management | Q36702081 |
| | Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 |
| | Management of RA medications in pregnant patients | Q37511730 |
| | Methotrexate nodulosis | Q38527495 |
| | Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists | Q39409324 |
| | Acidification of the endocytic and exocytic pathways | Q39459758 |
| | Inhibition of mitogen-activated protein kinase signaling by chloroquine | Q40733870 |
| | The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? | Q40951725 |
| | Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling | Q41337499 |
| | Capture and processing of exogenous antigens for presentation on MHC molecules. | Q41464375 |
| | Antimalarial drugs in the treatment of rheumatological diseases | Q41560764 |
| | Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual | Q41912319 |
| | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation | Q41913288 |
| | Multifocal electroretinographic evaluation of long-term hydroxychloroquine users | Q41913752 |
| | Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group | Q41915008 |
| | The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal | Q41915573 |
| | Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial | Q41917264 |
| | Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis | Q41917273 |
| | Evidence of transplacental passage of hydroxychloroquine in humans | Q41917690 |
| | Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. | Q41919391 |
| | Antimalarial drugs for rheumatoid arthritis | Q41920359 |
| | Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism | Q41921412 |
| | Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension | Q41924609 |
| | Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine | Q41925679 |
| | Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications | Q41930813 |
| | Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus | Q41935707 |
| | Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival | Q41941085 |
| | Pregnancy outcome following first trimester exposure to chloroquine | Q41942091 |
| | Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus | Q41942520 |
| | Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids | Q41943371 |
| | Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus | Q41944460 |
| | Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling | Q41944676 |
| | Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients | Q41945144 |
| | Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. | Q41945241 |
| | Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy | Q41946375 |
| | Successful Desensitization for Hydroxychloroquine Anaphylaxis | Q42920228 |
| | Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. | Q43417859 |
| | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases | Q43743058 |
| | Antimalarial agents in pregnancy | Q45712596 |
| | RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. | Q46687345 |
| | New insights into the antiviral effects of chloroquine. | Q46913485 |
| | Treatment of rheumatoid arthritis | Q56060521 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| | rheumatoid arthritis | Q187255 |
| | lupus erythematosus | Q188297 |
| | hydroxychloroquine | Q421094 |
| P304 | page(s) | 705-714 | |
| P577 | publication date | 2011-03-22 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy | |
| P478 | volume | 10 | |